Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP

October 9, 2026 7:00 AM

Seaport Therapeutics (Nasdaq: SPTX) presented Phase 1 pharmacokinetic (PK) data for its drug candidate GlyphAgo at the 39th European College ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found